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Abstract 
Objectives: The aim of this study is to review the available literature on the efficacy and 
safety of agents used for prevention of RAS. 
Background: Different vasodilator agents have been used to prevent radial artery spasm  
(RAS) in patients undergoing transradial cardiac catheterization.  
Methods: We included studies that evaluated any intra-arterial drug administered in the 
setting cardiac catheterization undertaken through the transradial access site (TRA). We also 
compared studies for secondary outcomes of major bleeding, procedure time, and procedure 
failure rate in setting of RAS prevention, patent hemostasis and radial artery occlusion. 
Results: 22 clinical studies met the inclusion criteria.  For placebo, RAS rate was 12% (4 
studies, 638 participants), which was similar to 2.5 mg of verapamil 12% (3 studies, 768 
participants) but greater than 5 mg of verapamil (4%, 2 studies, 497 participants).  For 
nicorandil, there was a much higher RAS rate compared to placebo (16%, 3 studies, 447 
participants).  The lowest rates of RAS was found for nitroglycerin at both 100 µg (4%) and 
200 µg (2%) doses, isosorbide mononitrate (4%) and nicardipine (3%).  We found no 
information regarding the procedure failure rates, patent hemostasis, and radial artery 
occlusion in these studies. 
Conclusions: In this largest and up-to-date review on intra-arterial vasodilators use to reduce 
RAS, we have found that the verapamil at a dose of 5 mg or verapamil in combination with 
nitroglycerine are the best combinations to reduce RAS.  
Keywords: vasodilator; radial artery catheterization; radial artery spasm 
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Introduction 
 The radial artery is fast becoming the preferred access site for performing coronary 
angiography and percutaneous coronary intervention (PCI) [1]. In UK, adoption of the 
transradial access site (TRA) for PCI has increased from 10% in 2006 to over 60% in 2012 
[2]. TRA is associated with reduced mortality and major adverse cardiac events (MACE) in 
selected cohorts at high risk of bleeding complications [2-4], thought to be related to a 
reduction in major access site related bleeding complications [1,5]. Transradial access is also 
associated with improved patient comfort and has also shown to be the preferred access site 
amongst patients undergoing PCI and be more cost effective than transfemoral access [6-8]. 
 However, TRA approach is not without limitations, it is associated with a longer 
learning curve and complex procedures requiring large bore guide catheters are not always 
possible particularly in patients with small diameter radial arteries. Furthermore operators 
may encounter radial artery spasm (RAS) [9] during TRA particularly at the beginning of the 
learning curve, or when encountering radial anomalies. A previous review of 19 papers with 
7,197 participants found that the incidence of RAS was 14.7% in patients in whom the radial 
artery was chosen as the access site for coronary angiography or PCI [10]. 
 RAS leads to patient discomfort, increased risk of vascular complications and 
procedure failure rate. Various drugs such as nitroglycerin, verapamil, isosorbide mononitrate 
are used to reduced the risk of RAS.  However, there is high variability in practice amongst 
operators for administration of these drugs. Furthermore, there are no guidelines or 
recommendations for using such drugs in day-to-day practice. Therefore, we conducted a 
systematic review of the available literature to evaluate the efficacy of agents used for 
prevention of RAS.  
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Methods 
 We searched MEDLINE and EMBASE on October 2014 using the broad search 
terms: "vasodilator" AND "radial artery occlusion" OR "radial artery spasm" OR 
"transradial."   The search results were reviewed by two independent judicators (CSK, MR) 
for studies that met the inclusion criteria and relevant reviews.  The bibliographies of 
included studies and relevant reviewers were screened for additional studies. 
 We included studies that evaluated any intra-arterial drug administered in the setting 
of TRA.  The inclusion criteria was  
1. Studies had to compare more than one agent or include a control group.  There was no 
restriction based on sample size. 
2. The studies had to evaluate some form of measure related to RAS such as incidence 
of RAS, change in diameter of radial artery and any adverse events associate with 
intra-arterial drug administration.  
 We excluded studies that administered drugs that were not intra-arterial and in-vitro 
studies.  
 Data was extracted from each study into preformatted spreadsheets.  The data 
collected was on the year, country, number of participants, age of participants, % of male 
participants, participant inclusion criteria, and type of treatments, efficacy outcomes and 
safety outcomes.  These results were narratively synthesized and trials with similar treatment 
arms were pooled using methods previous described [11]. 
 We also compared studies for secondary outcomes of procedure time, and procedure 
failure rate in setting of RAS prevention and radial artery occlusion. 
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Results 
 Our search yielded 123 relevant articles and after screening and reviewing full 
manuscripts, 21 articles met the inclusion criteria with 22 clinical studies [12-32].  The 
process of study selection is shown in Figure 1.   
 The study design and participant characteristics of the included trials is shown in 
Table 1. Majority of studies (n=14) used blinding and these studies took place between 1997-
2007 in different centers around the world.  There were a total of 8,777 participants (range of 
participants in each study 30 to 1,950) with an average age of 61 years and 70% were male 
participants.  All studies took place in the setting of transradial access (TRA). 
 Table 2 shows the different treatments that have been used as intra-arterial 
vasodilators and results from the studies.  Many agents were evaluated including verapamil, 
magnesium sulphate, nitroglycerin, nicorandil, diltiazem, isorobide mononitrate, petolamine, 
isosorbide dinitrate, molsidomine, nicardipine, placebo and combinations of these drugs as 
well as other drugs such as nitroprusside.  A variety of outcomes evaluated included any 
measure of changes in radial diameter, RAS rates, procedural success, blood pressure 
changes and radial occlusions and semi-occlusions. 
 Radial artery spasm was the most frequently evaluated outcome, which was evaluated 
for the efficacy of individual drugs in 14 studies (Table 3).  For placebo, RAS rate was 12% 
(4 studies, 638 participants), which was similar to 2.5 mg of verapamil 12% (3 studies, 768 
participants) but greater than 5 mg of verapamil (4%, 2 studies, 497 participants).  For 
nicorandil, there was a much higher RAS rate compared to placebo (16%, 3 studies, 447 
participants).  The lowest rates of RAS was found for nitroglycerin at both 100 µg (4%) and 
200 µg (2%) doses, isosorbide mononitrate (4%) and nicardipine (3%). 
 Combinations of different drugs were also evaluated in several studies[15,16,18-20] 
combining agents offered no advantage.  The best studied combination of verapamil and 
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nitroglycerin was evaluated in 5 studies [16,17,22-24].  The pooled results of these studies 
yielded 21% RAS rate (5 studies, 135/630) however, two studies[17,23] reported unusually 
high rates of RAS (71% and 52% respectively) and differed from the other studies because 
the verapamil dose was low (100 µg).  Excluding these studies the pooled rate of RAS for the 
verapamil/nitroglycerin combination was 9% (3 studies, 45/483). 
Other outcomes 
 Several studies evaluate outcomes other than RAS.  Abe et al found that ISDN was 
most potent vasodilator compared to verapamil, lignocaine and placebo [12].
 
While this study 
examined multiple doses, it was underpowered across each group.  Boyer et al found that a 
combination of nitroglycerin and verapamil was associated with greater vasodilation 
compared to placebo [13]. Byrne et al found that magnesium is a more potent vasodilator 
than verapamil [14]. Carrillo et al found similar vasodilation with nitroglycerin/verapamil and 
verapamil alone [15].
 
Dalal et al found similar decreases in radial artery diameter with 
nicorandil compared to nitroglycerin/diltizem but there is less blood pressure drop with 
nicorandil [19]. Dharma et al found similar rates of procedural success with nitroglycerin 
with and without diltiazem [20].
 
Sekai et al found greater vasodilation with nitroglycerine 
compared to ISDN and verapamil [29].  In addition, the adverse events reported in each 
included study are presented in Table 5. 
 We also analysed these studies for procedure failure rate i.e. switching from TRA to 
TRF, procedure duration, catheter information and radial artery occlusion, Table 4. Only four 
studies compared procedure duration out of which two studies showed it was non-significant 
in both treatment and placebo arms, Byrne et al reported increased procedure duration in 
treatment arm.  
 No information was available regarding the procedure failure rates and radial artery 
occlusion in these studies. 
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Discussion 
 In this largest and up-to-date review on intra-arterial vasodilators to reduce RAS, we 
have found that many agents have been evaluated as potential vasodilators to reduce RAS.  
We found that the pooled rate of RAS in the placebo arm of several studies was 12% and 
only 5 mg of verapamil had lower pooled rates of RAS (4%).  There were many single 
studies that evaluated the efficacy of different agents but many of these were underpowered. 
Nitroglycerin appears to reduce RAS but other less studied agents such as ISMN and 
nicardipine require further investigations.  Several different cocktails or combinations of 
drugs have been tried and the best combination is nitroglycerine and verapamil which lead to 
9% RAS if administered at adequate doses.  For other cocktails of medications, there is 
inconsistent evidence that one combination is superior to another.  
 Several previous reviews have evaluated RAS during transradial procedures.  The 
review by Ho et al reported that the incidence of RAS was 4 to 20%, which is consistent with 
the findings of 12% in the pooled results of the placebo arm of the current study [33]. The Ho 
et al review also discusses RAS prevention strategies including the use of pharmacological 
agents including intra-arterial vasodilatory cocktails but caution the use of verapamil because 
it is contraindicated in severe left ventricular function and bradycardia [33]. Another review 
by Kristic et al pooled the results from 19 studies had reported that the incidence of RAS was 
14.7% which is slightly higher than the current study [10]. The review by Kristic et al 
recommended that the combination of verapamil (1.25-5 mg) and nitroglycerin  (100-200 µg) 
can reduce RAS by up to 3.8% [10]. This combination is also supported by another review 
[34].  Our study supports the use of this combination of drugs at the recommended doses, as 
rate of RAS was 9% using this regime in the current study. 
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 The advantages and disadvantages of vasodilatory agents in preventing RAS has been 
previous reviewed [35]. Nitroglycerine or glycerine tri-nitrate promote smooth muscle 
relaxation and hence vasodilation but there are risks of tachyphylaxis, withdrawal and 
hypotension.  Verapamil is negatively inotropic and less effective than nifedipine but 
nifedipine is only available orally.  Nicardipine is a strong calcium antagonist while diltiazem 
is negatively inotropic, less potent and has a slow onset.  Nicorandil is less negatively 
inotropic compared to calcium channel antagonists.  While there is no clear agreement on the 
optimal agent, verapamil-glyceryl trinitrate may represents the optimal combination [35]. 
 While our study has shown that many intra-arterial agents can be used to prevent 
radial artery spasm, the use of sublingual agents in intractable cases of radial spasm is 
unclear.  There is a study by Al-Waili et al which found that sublingual verapamil and 
nifedipine may lower blood pressure in hypertensive patients and it may be possible that 
these agents could be used to reduce radial spasm [36].  It may be possible for use of 
sublingual nifedipine in cases of intractable radial artery spasm in hypertensive patients but 
more studies are needed. 
 Our study has several strengths and limitations.  This is the largest review with 22 
clinical trials with data from 8,777 participants.  We were able to pool the results for risk of 
RAS across many studies and found that the most effective agents appear to be verapamil 
alone or nitroglycerine and verapamil combination. 
 Our study is limited by the quality of the evidence available in literature.  There are 
several studies that are significantly underpowered.  There were as low as 30 patients in one 
study [15] and has low as 10 patients in each arm in another study [12]. Furthermore, many 
of the included studies were not fully published and were only available in abstract form. 
While, these studies may have limited information inclusion of these studies reduces 
publication bias. Furthermore, many of these studies were derived from well over a decade 
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ago and so the rates of 12% RAS reported in the placebo arms seem high in comparison to 
those encountered in daily practice by the authors of the manuscript. This may relate to the 
lack of radial specific equipment and sheaths used in these studies that would increase RAS 
rates, particularly when using sheaths without hydrophilic coatings [37]. An additional factor 
is that many centers use smaller diameter 5Fr radial sheaths and catheters for diagnostic 
cardiac catheterization that would decrease rates of RAS observed as would use of more 
contemporary thinner wall sheaths such as the Glidesheath Slender which combines an inner 
diameter compatible with 6Fr guiding catheter with an outer diameter close to current 5Fr 
sheaths where RAS rates have been reported as low as 4.4% [38]. Finally sheathless guide 
catheter usage may also result in lower rates of RAS than those reported in the ‘placebo’ 
control arm with previous data reporting RAS rates of 5% [39]. 
 No data were available about radial spasm and  radial artery occlusion in these studies 
in the setting of pharmacological prevention of RAS. Previous studies have suggested that 
RAS may increase the risk of radial artery occlusion, for example Rathore et al observed a 
high incidence of radial occlusion in patients with documented RAS in their randomized 
study investigating the influence of sheath coating and length on RAS rates (14.5% vs. 7.4%, 
p = 0.003) [37]. 
 Minimizing RAS either pharmacologically or via sheath/catheter selection certainly 
increases procedure success rate, reduces procedure duration and hence radiation exposure 
and minimizes the short and long term radial vascular complications. Our review highlights 
the gap in literature on these important outcomes in setting of reducing RAS 
pharmacologically and further studies are required to study this. 
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Conclusion 
 In this largest and up-to-date review on intra-arterial vasodilators use to reduce RAS, 
we have found that the verapamil at a dose of 5 mg or verapamil in combination with 
nitroglycerine are the best combinations to reduce RAS. The use of other agents to prevent 
RAS such as nicardipine, ISMN and magnesium requires more studies. Operators should 
consider optimal sheath and catheter selection, as well as pharmacological regime to 
minimize RAS particularly in procedures undertaken in patients at increased risk for RAS 
such as females, the elderly and those with small diameter radial artery sizes. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Acknowledgement: None. 
Funding: None. 
Disclosure statement: The authors report no financial relationships or conflicts of interest 
regarding the content herein. 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
References 
1. Mamas MA, Fraser DG, Ratib K, et al. Minimising radial injury: prevention is better 
than cure. Eurointervention. 2014;10:824-32. 
2. Ratib K, Mamas MA, Anderson SG, et al. Access site practice and procedural 
outcomes in relation to clinical presentation in 439,947 patients undergoing 
percutaneous coronary intervention in the United Kingdom. JACC Cardiovasc Interv 
2015;8:20-9. 
3. Mamas MA, Anderson SG, Car M, et al. Baseline bleeding risk and arterial access site 
practice in relation to procedural outcomes after percutaneous coronary intervention. J 
Am Coll Cardiol 2014;64:1554-64. 
4. Mamas MA, Anderson SG, Ratib K, et al. Arterial access site utilization in 
cardiogenic shock in the United Kingdom: is radial access feasible? Am Heart J 
2014;167:900-8. 
5. Chase AJ, Fretz EB, Warburton WP, et al. Association of the arterial access site at 
angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit 
Of Reduced Transfusion after percutaneous coronary intervention via the Arm or 
Leg). Heart 2008;94:1019–25. 
6. Cooper CJ, El-Shiekh RA, Cohen DJ, et al. Effect of transradial access on quality of 
life and cost of cardiac catheterization: a randomized comparison. Am Heart J 
1999;138:430–6.3.  
7. Rinfret S, Kennedy WA, Lachaine J, et al. Economic impact of same-day home 
discharge after uncomplicated transradial percutaneous coronary intervention and 
bolus-only abciximab regimen. JACC Cardiovasc Interv 2010;3:1011–9. 
8. Mitchell MD, Hong JA, Lee BY, Umscheid CA, Bartsch SM, Don CW. Systematic 
review and cost- benefit analysis of radial artery access for coronary angiography and 
intervention. Circ Cardiovasc Qual Outcomes 2012;5:454–62.  
9. Lo TS, Nolan J, Fountzopoulos E, et al. Radial artery anomaly and its influence on 
transradial coronary procedural outcome. Heart 2009;95:410-5. 
10. Kristic I, Lukenda J. Radial artery spasm during transradial coronary procedures. J 
Invasive Cardiol 2011;23:527-31. 
11. Kwok CS, Holland R, Gibbs S. Efficacy of topical treatments for cutaneous warts: a 
meta-analysis and pooled analysis of randomized controlled trials. Br J Dermatol 
2011;165:233-246. 
12. Abe S, Meguro T, Endoh N, et al. Response of the radial artery to three vasodilatory 
agents. Catheter Cardiovasc Interv 2000;49:253-256.  
13. Boyer N, Beyer A, Gupta V, et al. The effects of intra-arterial vasodilators on radial 
artery size and spasm: implications for contemporary use of trans-radial access for 
coronary angiography and percutaneous coronary intervention. Cardiovasc Revasc 
Med 2013;14:321-324. 
14. Byrne J, Spence M, Haegeli L, et al. Magnesium sulphate during transradial cardiac 
catherization: a new use for an old drug. J Invasive Cardiol 2008;20:539-542. 
15. Carrilo X, Fernandez-Nofrerias E, Ciompi F, et al. Changes in radial artery volume 
assessed using intravascular ultrasound: a comparison of two vasodilator regimens in 
transradial coronary interventions. J Invasive Cardiol 2011;23:401-404. 
16. Chen CW, Lin CL, Lin TK, Lin CD. A simple and effective regimen for prevention of 
radial artery spasm during coronary catheterization. Cardiology 2006;105:43-47. 
17. Cho YC, Kim W, Kim JT, et al. The clinical effects and radial artery vasodilation 
after high dose nicorandil solution during coronary angiography via the radial artery. 
Korean Circ J 2008;38:191-196.  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
18. Coppola J, Patel T, Kwan T, et al. Nitroglycerin, nitroprusside, or both, in preventing 
radial artery spasm during transradial artery catheterization. J Invasive Cardiol 
2006;18:155-8. 
19. Dalal JJ, Wani SP, Nair P, Pillai S, Hansara S. Safety and efficacy of radial arterial 
injection of nicorandil compared to the usual cocktail of nitroglycerine (NTG) and 
diltiazem given during radial angiography. J Am Coll Cardiol 2011;58:B142. 
20. Dharma S, Shah S, Radadiya R, Vyas C, Pancholy S, Patel T. Nitroglyerin plus 
diltiazem versus nitroglycerin alone for spasm prophylaxis with transradial approach. 
J Invasive Cardiol 2012;24:122-125.  
21. Hizoh I, Majoros Z, Major L, et al. Need for prophylactic application of verapamil in 
transradial coronary procedures: a randomized trial. J Am Heart Assoc 
2014;3:e000588.  
22. Kiemeneij F, Vajifdar BU, Eccleshall SC, Laarman GJ, Slagboom T, van der Wieken 
R. Evaluation of a spasmolytic cocktail to prevent radial artery spasm during coronary 
procedures. Catheter Cardiovasc Interv 2003;58:281-284. 
23. Kim SH, Kim EJ, Cheon WS, et al. Comparative study of nicorandil and a 
spasmolytic cocktail in preventing radial artery spasm during transradial coronary 
angiography. Int J Cardiol 2007;120:325-330.  
24. Manickam K. Efficacy of nicorandil in preventing radial artery spasm during 
transradial interventions. Eurointervention 2011;7:M190. 
25. Mont'Alverne Filho JR. Assad JA, Zago AC, et al. Compariative study of the use of 
diltiazem as a antispasmodic drug in coronary angiography via the transradial 
approach. Arg Bras Cardiol 2003;81:59-63. 
26. Rosencher J, Huber A, Chaib A, et al. Diltiazem, verapamil or dinitrate isosorbid for 
prevention of radial artery spasm in percutaneous coronary intervention. J Am Coll 
Cardiol 2012;60:B117-B118. 
27. Rosencher J. How to choose the best antispastic agent to prevent radial artery spasm 
during PCI? The SPASM3 study. Eurointervention 2013;9:201.  
28. Ruiz-Salmeron RJ, Mora R, Masotti M, Betriu A. Assessment of the efficacy of 
phenotolamine to prevent radial artery spasm during cardiac catheterization 
procedures: a randomized study comparing phentolamine vs. verapmil. Catheter 
Cardiovasc Interv 2005;66:192-198. 
29. Sakai H, Ohe H, Harada T, et al. Radial artery dilatation: comparison of three drugs. 
Jap J Interv Cardiol 1999;14:247-251.  
30. Varenne O, Jegou A, Cohen R, et al. Prevention of arterial spasm during percutaneous 
coronary interventions through radial artery: the SPASM study. Catheter Cardiovasc 
Interv 2006;68:231-235.  
31. Varenne O, Diallo A, Jakamy R, Rosencher J, Jegou A, Allouch P. How to limit 
radial artery spasm in patients treated by transradial interventions. J Am Coll Cardiol 
2014;64:B240.  
32. Xiaolong L, Bin W. Analysis of radial artery spasm and vasodilator intervention 
study. Heart 2012;98:D164. 
33. Ho HH, Jafary FH, Ong PJ. Radial artery spasm during transradial cardiac 
catheterization and percutaneous intervention: incidence, predisposing factors, 
prevention and management. Cardiovasc Revasc Med. 2012;13:193-195. 
34. Vuurmans T, Hilton D. Brewing the right cocktails for radial intervention. Indian 
Heart J 2010;62:221-226. 
35. Attaran S, John L, El-Gamel A. Clinical and potential use of pharmacological agents 
to reduce radial artery spasm in coronary artery surgery. Ann Thorac Surg 
2008;85:1483-9. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
36. Al-Waili NS, Hasan NA. Efficacy of sublingual verapamil in patients with severe 
essential hypertension: comparison with sublingual nifedipine. Eur J Med Res 
1999;4:193-8. 
37. Rathore S, Stables RH, Pauriah M, et al. Impact of length and hydrophilic coating of 
the introducer sheath on radial artery spasm during transradial coronary intervention: 
a randomized study. JACC Cardiovasc Interv 2010;3:475-83. 
38. Aminian A, Dolatabadi D, Lefebvre P, et al. Initial experience with the Glidesheath 
Slender for transradial coronary angiography and intervention: a feasibility study with 
prospective radial ultrasound follow-up study. Catheter Cardiovasc Interv 
2014;84:436-42. 
39. Mamas M, D'Souza S, Hendry C, et al. Use of the sheathless guide catheter during 
routine transradial percutaneous coronary intervention: a feasibility study. Catheter 
Cardiovasc Interv 2010;75:596-602. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Table 1: Study design and participant characteristics of studies which evaluated intra-arterial vasodilators. 
 
Study ID Design Year Country No. of 
participants 
Mean age % male Participants 
Abe 2000 [12] RCT 1997 Japan 100 64 64 Transradial catheterization. 
Boyer 2013 [13] Blinded RCT NR USA 121 61 65 Transradial catheterization. 
Byrne 2008 [14] Double blind RCT 2007 Researchers 
from Canada 
and UK. 
86 NR NR Transradial catheterization. 
Carrilo 2011 [15] Double blind RCT NR Spain 30 63 77 Transradial catheterization. 
Chen 2006 [16] Blinded RCT 2002-2003 Taiwan 361 64 68 Transradial catheterization. 
Cho 2008 [17] RCT 2007 Korea 142 64 74 Transradial catheterization. 
Coppola 2006 
[18] 
Double blind RCT NR NR 379 57 83 Transradial catheterization. 
Dalal 2011 [19] Single blind trial NR India 200 NR NR Transradial catheterization. 
Dharma 2012 [20] Double blind RCT NR Indonesia 150 58 72 Transradial catheterization. 
Hizoh 2014 [21] Double blind RCT NR Hungary 591 62 64 Transradial catheterization. 
Kiemeneij 2003 
[22] 
Non-randomized, 
non-blinded trial 
NR Netherlands 100 64 75 Transradial catheterization. 
Kim 2007 [23] Double blind RCT 2005 Korea 150 60 53 Transradial catheterization. 
Manickam 2011 
[24] 
Non-randomized, 
non-blinded trial 
NR India 600 NR NR Transradial catheterization. 
Mont'AlverneFino 
2003 [25] 
Double blind RCT 2000-2001 Brazil 51 56 74 Transradial catheterization. 
Rosencher 2012 
[26] 
Double blind RCT NR France 332 NR NR Transradial catheterization. 
Rosencher 2013 
SPASM 3 [27] 
RCT NR France 731 NR NR Transradial catheterization. 
Ruiz-Salmeron 
2005 [28] 
Double blind RCT 2003-2004 Spain 500 63 76 Transradial catheterization. 
Sakai 1999 [29] Non-randomized, 
non-blinded trial 
NR Japan 186 NR NR Transradial catheterization. 
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Varenne 2006 
SPASM 1 [30] 
Double blind RCT 2003 France 1219 60 75 Transradial catheterization. 
Varenne 2006 
SPASM 2 [30] 
Double blind RCT 2004-2005 France 618 62 70 Transradial catheterization. 
Varenne 2014 
[31] 
RCT NR France 1950 NR NR Transradial catheterization. 
Xiaolong 2012 
[32] 
RCT NR China 180 NR 54 Transradial catheterization. 
RCT=randomized controlled trial, NR=not reported 
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Table 2: Intra-arterial vasodilator treatments, results and interpretation. 
 
Study ID Treatments Results Interpretation 
Abe 2000 [12] Saline, ISDN 1 mg, 3 mg, 5 mg, verapamil 1 
mg, 3 mg, 5 mg, lidocaine 10 mg, 30 mg, 50 
mg, n=10 in each group. 
Change ratio: (diameter after drug injection - diameter 
before drug injection) x 100/(diameter before drug 
injection) for proximal and distal: saline 3.1%/6.1%, 
ISDN 1 mg 19.1%/20.3%, 3 mg 17.4%/18.6%, 5 mg 
31.0%/28.8%, verapamil 1 mg 6.4%/14.6%, 3 mg 
4.3%/7.6%, 5 mg 9%/10.8%, lignocaine 10 mg -15.6%/-
12.1%, 30 mg -12.7%/-17.3%, 50 mg -7.3%/-1.6%.  
ISDN was most potent vasodilator 
compared to verapamil, lignocaine 
and placebo. 
Boyer 2013 [13] Verapamil 200ug/nitroglycerin 200ug 
(n=43), placebo (n=78) 
Radial artery origin: no vasodilator 2.09±0.41 mm, 
vasodilator 2.29±0.47 mm, p=0.022. Radial artery 
narrowest segment: no vasodilator 1.39±0.43 mm, 
vasodilator 1.83±0.56, p<0.001 mm. 
Nitroglycerin and verapamil was 
associated with greater vasodilation 
compared to placebo. 
Byrne 2008 [14] Verapamil 1 mg, magnesium sulphate 150 
mg. 
Increase in radial artery: magnesium 0.36±0.03mm, 
verapamil 0.27±0.03mm, p<0.05. Decrease in MAP with 
verapamil -6.6±1.4 mmHg, p<0.01, magnesium -0.25±1.4 
mmHg, p=NS. Vagal reaction requiring IV atropine: 
verapamil 3, magnesium 1. 
Magnesium is a more potent 
vasodilator than verapamil. 
Carrilo 2011 [15] Nitroglycerin 200 ug/verapamil 2.5 mg 
(n=15), verapamil 2.5 mg (n=15). 
Relative diameter increase: nitroglycerin/verapamil 
6.6±6.7, verapamil 8.6±14.5, p=0.69. 
Similar vasodilation can be achieved 
with verapamil with and without 
nitroglycerin. 
Chen 2006 [16] Nitroglycerin 100ug/verapamil 1.25 mg 
(n=133), nitroglycerin 100ug (n=135), 
placebo (n=93). 
RAS rate: nitroglycerin/verapamil 5/133, nitroglycerin 
6/135, placebo 19/93. 
Similar rates of RAS with 
nitroglycerin with and without 
verapamil which were lower than 
placebo. 
Cho 2008 [17] Nicorandil 12 mg (n=72), nitroglycerin 
200ug/verapamil 100ug (n=72). 
Change in radial artery diameter as proximal segment: 
nicorandil 1.58 to 1.92 mm, nitroglycerin/verapamil 1.67 
to 1.93 mm. Change of minimal luminal diameter: 
nicorandil 0.63 vs nitroglycerin/verpamil 0.48. RAS rate 
(proximal and middle segment): nicorandil 37/72, 
nitroglycerin/verapamil 51/72, proximal only nicorandil 
22/72, nitroglycerin/verapamil 24/72, middle segment 
nicorandil 15/72, nitroglycerin/verapamil 27/72. 
Nicorandil is not superior to 
nitroglycerin and verapamil as a 
vasodilator. 
Coppola 2006 
[18] 
Nitroglycerin 100 ug/diltiazem 5 mg 
(n=123), nitroprusside 100 ug/diltiazem 5 
mg (n=119), nitroglycerin 100 
ug/nitroprusside 100ug/diltiazem 5 mg 
Radial artery diameter: nitroglycerin/diltiazem 2.37 mm, 
nitroprusside/diltiazem 2.36 mm, 
nitroglycerin/nitroprusside/diltiazem 2.33mm. RAS rate: 
nitroglycerin/diltiazem 15/123, nitroprusside/diltiazem 
No improvement in RAS with 
nitroglycerin/diltiazem, 
nitroprusside/diltiazem and 
nitroglycerin/nitroprusside/diltiazem. 
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(n=137). 16/119, nitroglycerin/nitroprusside/diltiazem 13/137. 
Dalal 2011 [19] Nitroglycerin 200 ug/diltiazem 5 mg 
(n=100), nicorandil 4 mg (n=100). 
Decrease in radial artery diameter in proximal segment: 
nitroglycerin/diltiazem 80±48%, nicorandil 80±37%. 
Decrease in systolic blood pressure: 
nitroglycerin/diltiazem 13±9, nicorandil 6±5. 
Similar decreases in radial artery 
diameter with nicorandil compared 
to nitroglycerin/diltizem but there is 
less blood pressure drop with 
nicorandil. 
Dharma 2012 [20] Nitroglycerin 200 ug/diltiazem 2.5 mg 
(n=75), nitroglycerin 200 ug (n=75). 
Procedural success 100% in both groups. Systolic BP 
nitroglycerin/diltiazem 162.68±27.68 to 125.56±21.30 
mmHg, nitroglycerin 161.12±27.54 to 141.24±26.15 
mmHg.  Diastolic BP nitroglycerin/diltiazem 80.11±11.03 
to 71.60±11.21 mmHg, nitroglycerin 78.31±13.61 to 
75.88±11.45 mmHg. Heart rate nitroglycerin/diltiazem 
81.69±18.37 to 86.61±18.05, nitroglycerine 81.61±17.27 
to 84.69±18.08. 
Similar rates of procedural success 
with nitroglycerin with and without 
diltiazem. 
Hizoh 2014 [21] Verapamil 5 mg (n=294), placebo (n=297). RAS rate: verapamil 5/294 (1.0%), placebo 3/297 (1.7%). Lower rates of RAS with verapamil 
compared to placebo. 
Kiemeneij 2003 
[22] 
Verapamil 5 mg/nitroglycerin 200 ug 
(n=50), placebo (n=50). 
Maximum pullback force: verapamil/nitroglycerine 
0.53±0.52, placebo 0.76 ± 0.45. RAS rate: 
verapamil/nitroglycerin 4/50, placebo 11/50. 
RAS lower with 
verapamil/nitroglycerin compared to 
placebo. 
Kim 2007 [23] Nicorandil 4 mg (n=75), verapmil 200 ug 
(n=75). 
Blood pressure change: nicorandil reduced by 15.4±11.5 
mmHg, verapamil reduced by 16.3±13.4 mmHg. Change 
in diameter: proximal nicorandil 2.59±0.49 mm to 2.91 
±0.48 mm, verapamil 2.62±0.57 mm to 2.89±0.56 mm. 
Mid-segment increase nicorandil was 0.34±0.23 mm, 
verapamil 0.24±0.15 mm. RAS rate: nicorandil 39/75 
(50.7%) vs verapamil 39/75 (52%). 
Similar RAS rates with nicorandil 
and verapamil. 
Manickam 2011 
[24] 
Verapamil/nitroglycerin (likely n=300), 
nicorandil 2 mg (likely n=300). 
RAS rate: nicorandil 3% (likely 9/300), 
verapamil/nitroglycerin 12% (likely 36/300). 
RAS lower with nicorandil 
compared to verapamil/nitroglycerin. 
Mont'AlverneFino 
2003 [25] 
ISMN (n=23), diltiazem/ISMN (n=27). Radial artery diameter: ISMN before 2.39±0.45 mm after 
2.35±0.47 mm, diltiazem/ISMN before 2.15±0.32 mm 
after 2.46±0.39 mm. Radial artery output ISMN before 
7.07±5.37 ml/min after 5.89±3.33 ml/min, 
diltiazem/ISMN before 5.74±2.79 ml/min after 9.06±7.78 
ml/min. RAS rate: ISMN 1/23, diltiazem/ISMN 0/27. 
Radial spasm, occlusion, partial occlusion: ISMN 4/23, 
diltiazem/ISMN 0/27. 
RAS rates similarly low in ISMN 
and diltiazem ISMN but study is 
underpowered. 
Rosencher 2012 
[26] 
Diltiazem 5 mg (n=117), verapamil 2.5 mg 
(n=109), ISDN 1 mg (n=106). 
RAS rate (severe and minor): ISDN 22/106 (21%), 
verapamil 23/109 (21%), diltiazem 42/117 (26%). 
Higher rates of RAS with diltiazem 
compared to ISDN and verapamil. 
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Rosencher 2013 
SPASM 3 [27] 
Diltiazem (n=252), verapamil (n=235), 
ISDN (n=244). 
RAS rate: diltiazem 67/252 (26.6%), verapamil 38/235 
(16.2%), ISDN 42/244 (17.2%). 
Higher rates of RAS with diltiazem 
compared to ISDN and verapamil. 
Ruiz-Salmeron 
2005 [28] 
Petolamine 2.5 mg (n=250), verapamil 2.5 
mg (n=250). 
Change in diameter petolamine 12.6±12.9%, verapamil 
13.6±14.5%. RAS rate: verapamil 33/250 (13.2%), 
pentolamine 58/250 (23.2%). Radial semiocclusion and 
occlusion: verapamil 19/250 (7.7%), pentolamine 16/250 
(6.4%). 
Radial semi-occlusion and occlusion 
with verapamil and pentolamine. 
Sakai 1999 [29] ISDN 1m g, nitroglycerin 1 mg, verapamil 5 
mg. 
Enlargement greatest with nitroglycerine 12.7% vs ISDN 
and verapamil. 
Greater vasodilation with 
nitroglycerine compared to ISDN 
and verapamil. 
Varenne 2006 
SPASM 1 and 2 
[30] 
Verapamil 2.5 mg (n=409), verapamil 5 mg 
(n=203), molsidomine 1 mg (n=203), 
verapamil 2.5 mg/molsidomine 1 mg 
(n=206), placebo (n=198). 
RAS rate: placebo 44/198 (22.2%), verapamil 2.5 mg 
34/409 (8.3%), verapamil 5 mg 16/203 (7.9%), 
mosidomine 1 mg 27/203 (13.3%), 
verapamil/mosidomine 10/206 (4.9%).  No difference in 
symptomatic hypotension. 
RAS is lowest with 
verapamil/mosidomine combination. 
Varenne 2014 
[31] 
Diltiazem, verapamil, mosidomine, 
isosorbidedinitrate or placebo. 
RAS rate: placebo 44/198 (22.2%), molsidomine 27/203 
(13%), verpamil 88/847 (10.4%), similiar for placebo 
ISDN and diltiazem. Significant blood pressure fall 
occurred more with diltiazem and ISDN. 
RAS lowest with verapamil and/or 
molsidomine and ISDN and 
diltiazem should be not be used. 
Xiaolong 2012 
[32] 
Nitroglycerine 200 ug (n=60), nicardipine 
200ug (n=60), nicardipine 
200ug/nitroglycerine 100 ug (n=60). 
RAS rate: baseline nitroglycerin 9/60 (15%), nicardipine 
5/60 (8.3%), combination 5/60 (8.3%), 2 min 
nitroglycerin 1/60 (1.7%), nicardipine 2/60 (3.3%) and 
combination 0/60 (0%). 
Nitroglycerin and nicardipine are 
effective at lowering RAS but 
combination is best. 
ISDN=isosorbide dinitrate, MAP=mean arterial pressure, ISMN=isosorbide mononitrate, RAS=radial artery spasm 
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Table 3: Single intra-arterial agents and rates of radial artery spasm stratified by whether there were single or multiple study results.  
 
Intra-arterial agent Total studies Total RAS Total participants Rate of RAS 
Multiple studies 
Placebo 4 77 638 0.12 
Verapamil 2.5 mg 3 90 768 0.12 
Verapamil 5 mg 2 21 497 0.04 
Nicorandil (variable dose) 3 70 447 0.16 
Single studies 
Nitroglycerin 100 µg 1 6 135 0.04 
Nitroglycerin 200 µg 1 1 60 0.02 
ISMN 1 1 23 0.04 
Diltiazem 1 67 252 0.27 
Nicardipine 1 2 60 0.03 
Pentolamine 1 58 250 0.23 
Mosidomine 1 23 203 0.11 
RAS=radial artery spasm 
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Table 4: Other outcomes of studies which evaluated intra-arterial vasodilators. 
 
Study ID Procedure time Bleeding reported Sheath information Procedure Failure Radial 
occlusion  
Abe 2000 [12] NA NA NA NA NA 
Boyer 2013 [13] NA NA Terumo glidesheath NA NA 
Byrne 2008 [14] Longer in treatment arm NA Hydrophilic sheaths in treatment arm  NA NA 
Carrilo 2011 [15] NA NA Hydrophilic sheaths both arms NA NA 
Chen 2006 [16] NA NA Hydrophilic sheaths both arms NA NA 
Cho 2008 [17] Longer in placebo arm NA NA NA NA 
Coppola 2006 
[18] 
Recorded but not quoted in paper NA Non hydrophilic sheaths all arms NA NA 
Dalal 2011 [19] NA NA NA NA NA 
Dharma 2012 
[20] 
NA NA Hydrophilic sheaths  NA NA 
Hizoh 2014 [21] Not significant both arms NA NA Not significant both arms NA 
Kiemeneij 2003 
[22] 
Not significant both arms NA NA NA NA 
Kim 2007 [23] NA NA NA NA NA 
Manickam 2011 
[24] 
NA NA NA NA NA 
Mont'AlverneFin
o 2003 [25] 
NA NA NA NA NA 
Rosencher 2012 
[26] 
NA NA NA Not significant NA 
Rosencher 2013 
SPASM 3 [27] 
NA NA NA NA NA 
Ruiz-Salmeron 
2005 [28] 
NA NA NA Significant in treatment arm NA 
Sakai 1999 [29] NA NA NA NA NA 
Varenne 2006 
SPASM 1 and 2 
[30] 
NA NA Hydrophilic sheaths  NA NA 
Varenne 2014 
[31] 
Not significant both arms Not significant 
both arms 
Hydrophilic sheaths NA NA 
Xiaolong 2012 NA NA NA NA NA 
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[32] 
NA=not available 
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Table 5: Adverse events reported by included studies 
 
Study ID Adverse events 
Abe 2000 [12] All patients who received ISDN complained of a cold sensation, and all that 
received verapamil complained of a hot sensation at the injection site of the 
forearm. 
Boyer 2013 [13] There were no access related complications for either group. 
Byrne 2008 [14] Administration of verapamil resulted in a fall in mean arterial pressure (change 
in MAP -6.6±1.4 mmHg; p<0.01), whereas magnesium did not have a significant 
hemodynamic effect (change in MAP -0.25±1.4 mmHg; p=NS). No change in 
heart rate was seen following administration of either drug (change in HR 
following study drug; magnesium +0.4±1.5 bpm versus verapamil -0.8±0.9 bpm; 
p=NS). Three patients in the verapamil group and 1 in the magnesium group 
suffered vagal reactions requiring treatment with intravenous atropine. Mean 
pain scores were similar between both groups. Severe arm pain (pain score>5) 
was observed in 14 (30%) patients receiving verapamil and 9 (27%) receiving 
magnesium (p=NS). 
Carrillo 2011 [15] No adverse events reported. 
Chen 2006 [16] No adverse events reported. 
Cho 2008 [17] The reductions in the systolic and diastolic blood pressure 1 minute after drug 
administration were 33.6±11.4/10.4±7.7 mmHg in the Nicorandil group and 
12.8±9.8/3.8±5.3 mmHg in the Cocktail group (p<0.001). 
Coppola 2006 
[18] 
No adverse events reported. 
Dalal 2011 [19] No edema was observed in the nitroglycerin and diltiazem group, though 3 
patients in the nicorandil group developed edematous swelling locally.  
Significantly greater increase in heart rate (11±11 vs 5±4, p<0.001) and systolic 
blood pressure (13±9 vs 6±5, p<0.001) in the nitroglycerin and diltiazem group 
compared to nicorandil group. 
Dharma 2012 [20] Diltiazem and nitroglycerin vs nitroglycerin significant difference in systolic 
blood pressure (124.56±21.30 vs 141.24±26.15, p<0.001)  and diastolic blood 
pressure (71.60±11.21 vs 75.88±11.45, p=0.022 but not heart rate (86.61±18.05 
vs 84.69±18.08, p=0.516) after cocktail.  Vasovagal reaction was higher (3% vs 
0%, p=0.497) but not significant in diltiazem and nitroglycerin but there was 
significantly more local burning pain (21% vs 9%, p=0.041). 
Hizoh 2014 [21] There was no considerable difference in the rates of “significant pain” defined as 
pain score ≥4 on the 1-to-6 scale (Fisher’s exact test, placebo 8.8% versus 
verapamil 7.1%, p=0.45). 
Kiemeneij 2003 
[22] 
More pain (score ≥III) in no cocktail group compared to nitroglycerin and 
verapamil (34% vs 14%, p=0.019) and pain score was higher in no cocktail 
group (2.08±1.07 vs 1.7±0.94, p=0.03). 
Kim 2007 [23] No significant differences in the mean change of systolic blood pressure (p=0.61) 
and diastolic blood pressure (p=0.27) were observed between the two groups. 
Manickam 2011 
[24] 
No adverse events reported. 
Mont'AlverneFino 
2003 [25] 
Only 1 patient (2%) from placebo group had hypotension after injection of the 
solution.  A small hematoma was observed at the site of puncture in 2 cases (4%) 
but unclear in which group. 
Rosencher 2012 
[26] 
There was also no significant difference in term of safety events and pain 
sensation between the different groups. 
Rosencher 2013 
SPASM 3 [27] 
No significant difference was found between the three groups in terms of severe 
pain, crossover and safety events. 
Ruiz-Salmeron 
2005 [28] 
There were only two serious events related to the procedure: one patient 
presented an extensive hematoma in the right forearm produced by radial 
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perforation and was managed conservatively; another patient developed a 
transient cerebrovascular accident, with no permanent sequel. Mean aortic 
pressure drop after vasodilator was greater in the phentolamine group compared 
to verapamil (14.2±8.0 vs 8.8±6.8, p<0.001). 
Sakai 1999 [29] No adverse events reported. 
Varenne 2006 
SPASM 1 and 
SPASM 2 [30] 
Symptomatic hypotension occurred in 73 patients (6%) with no difference 
between groups. Morphine chlorydrate was administered because of per-
procedural arm pain in 36 patients (3%) with no difference between groups. 
Minor hematomas were noted in 70 patients (5.7%), and the absence of a left 
radial pulse with no ischemia occurred in 12 (1%). 
Varenne 2014 
[31] 
Significant fall of blood pressure occurred significantly more with diltiazem and 
ISDN compared to placebo or other vasodilators (p=0.001). 
Xiaolong 2012 
[32] 
No adverse events reported. 
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Figure 1: Flow diagram of study selection 
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Highlights 
 Radial artery spasm(RAS) causes procedural failure in transradial catheterization.  
 RAS may complicate 10-15% procedures undertaken through the radial approach.  
 We reviewed the efficacy of vasodilators that have been used to minimize RAS.   
 The pooled RAS rate was lowest with 5 mg of verapamil(4%) compared to 
placebo(12%). 
 The best combination of drugs to minimize RAS is nitroglycerine and verapamil.  
